ACM
ALNY icon

ADAR1 Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

ADAR1 Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-234,400
Closed -$35M – 270
2024
Q1 		$35M Buy
234,400
+5,800
+3% +$968K 7.95% 1
2023
Q4 		$43.8M Buy
+228,600
New +$38.9M 15.64% 1

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ADAR1 Capital Management's ALNY Position: Q1 2025 in Review

ADAR1 Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2025, closing a stake of 2,900 shares — an estimated $682K sold.

ADAR1 Capital Management first reported a position in ALNY in Q4 2023 and held it in 4 quarters. The position peaked at $26.9M in Q1 2024. 627 funds tracked by Wall St. Rank hold ALNY as of Q1 2025.

  • ADAR1 Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • ADAR1 Capital Management sold 2,900 Alnylam Pharmaceuticals shares in Q1 2025, an estimated $682K.
  • ADAR1 Capital Management first reported a position in Alnylam Pharmaceuticals in Q4 2023 and held it in 4 quarters.
  • ADAR1 Capital Management's Alnylam Pharmaceuticals position peaked at $26.9M in Q1 2024.
  • 627 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2025.

Based on ADAR1 Capital Management's 13F filing for Q1 2025, filed 15 May 2025.